RT
RCKT icon

Robert Torray’s Rocket Pharmaceuticals RCKT Stock Holding History

Robert Torray’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-117,301
Closed -$782K – 105
2025
Q1 		$782K Sell
117,301
-4,794
-4% -$47.4K 0.12% 84
2024
Q4 		$1.53M Buy
122,095
+48,671
+66% +$733K 0.22% 76
2024
Q3 		$1.36M Buy
73,424
+6,208
+9% +$127K 0.19% 83
2024
Q2 		$1.45M Buy
67,216
+6,283
+10% +$144K 0.22% 81
2024
Q1 		$1.64M Buy
60,933
+77
+0.1% +$2.19K 0.25% 73
2023
Q4 		$1.82M Buy
60,856
+679
+1% +$15K 0.3% 67
2023
Q3 		$1.23M Buy
60,177
+5,608
+10% +$102K 0.22% 81
2023
Q2 		$1.08M Buy
54,569
+337
+0.6% +$6.81K 0.19% 83
2023
Q1 		$929K Sell
54,232
-92
-0.2% -$1.8K 0.17% 90
2022
Q4 		$1.06M Sell
54,324
-2,627
-5% -$48.4K 0.19% 87
2022
Q3 		$909K Sell
56,951
-3,524
-6% -$55K 0.18% 89
2022
Q2 		$832K Buy
60,475
+16,820
+39% +$201K 0.16% 93
2022
Q1 		$692K Buy
43,655
+7,206
+20% +$124K 0.11% 96
2021
Q4 		$796K Sell
36,449
-1,333
-4% -$36.4K 0.12% 98
2021
Q3 		$1.13M Buy
37,782
+422
+1% +$15.4K 0.17% 93
2021
Q2 		$1.66M Buy
37,360
+8,299
+29% +$360K 0.24% 87
2021
Q1 		$1.29M Sell
29,061
-5,403
-16% -$297K 0.2% 92
2020
Q4 		$1.89M Sell
34,464
-14,331
-29% -$522K 0.31% 67
2020
Q3 		$1.11M Buy
48,795
+218
+0.4% +$5.37K 0.2% 87
2020
Q2 		$1.02M Sell
48,577
-7,881
-14% -$142K 0.19% 88
2020
Q1 		$788K Buy
56,458
+26,400
+88% +$523K 0.17% 88
2019
Q4 		$684K Buy
+30,058
New +$502K 0.12% 92

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Robert Torray's RCKT Position: Q2 2025 in Review

Robert Torray sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 117,301 shares — an estimated $782K sold.

Robert Torray first reported a position in RCKT in Q4 2019 and held it in 22 quarters. The position peaked at $1.89M in Q4 2020. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Robert Torray reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Robert Torray sold 117,301 Rocket Pharmaceuticals shares in Q2 2025, an estimated $782K.
  • Robert Torray first reported a position in Rocket Pharmaceuticals in Q4 2019 and held it in 22 quarters.
  • Robert Torray's Rocket Pharmaceuticals position peaked at $1.89M in Q4 2020.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Torray Investment Partners's 13F filing for Q2 2025, filed 5 Aug 2025.